search
GLP-1 receptor agonists
Trends
- 1Oral GLP-1 drug safiglipron shows promise in early type 2 diabetes trial●Oral small-molecule GLP-1 receptor agonist safiglipron in early type 2 diabetes: a randomized, double-blind, placebo-controlled trial
A randomized, double-blind, placebo-controlled trial published in Nature reports that safigliptron, an oral small-molecule GLP-1 receptor agonist, was tested in people with early type 2 diabetes. The publication is drawing attention as GLP-1 drugs reshape diabetes and obesity treatment, and an oral small-molecule option could be easier to take than injectable alternatives. Details on efficacy and safety are being reviewed by clinicians and researchers.
- 2Retatrutide Shows Record Weight Loss in Type 2 Diabetes Trial▼Triple Agonist Retatrutide Pushes Weight Loss to New Levels in Type 2 Diabetes
Eli Lilly's triple agonist retatrutide has been reported to push weight loss to new levels among patients with type 2 diabetes, according to Inside Precision Medicine. The drug, which targets three hormone receptors, is being studied as one of the most powerful obesity and diabetes treatments in development, extending gains seen with tirzepatide and semaglutide.